Day One Biopharmaceuticals I (DAWN) Technical Analysis
$6.51▲0.62%
Market is closed - opens 7 PM, 01 Jul 2025
Insights
- Day One Biopharmaceuticals I is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Day One Biopharmaceuticals I stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Day One Biopharmaceuticals I stock is Range bound.
- Based on analysis of the Pivot Points, the current market trend for Day One Biopharmaceuticals I stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 43.69 | Neutral |
Stochastic | 22.5, 21.94 | Neutral |
Ultimate Oscillator | 59.55 | Neutral |
Stochastic Relative Strength Index | 26.65, 25.37 | Neutral |
Moving Average Convergence Divergence | -0.11, -0.1 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 6.49 | Sell |
20 | 6.69 | Sell |
50 | 6.8 | Sell |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 6.52 | Sell |
20 | 6.59 | Sell |
50 | 7.0 | Sell |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 6.46 | Neutral |
20 | 6.67 | Neutral |
50 | 6.76 | Neutral |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 6.43 | Sell |
20 | 6.46 | Buy |
50 | 6.03 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 6.41 | Sell |
20 | 6.5 | Buy |
50 | 6.36 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 6.69 |
Resistance L2 | 6.59 |
Resistance L1 | 6.54 |
Pivot Point | 6.44 |
Support L1 | 6.39 |
Support L2 | 6.29 |
Support L3 | 6.24 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.